



EPTIVA THERAPEUTICS ANNOUNCES LICENSING AGREEMENT FOR EXCLUSIVE WORLDWIDE RIGHTS TO CLINICAL STAGE PERSONALIZED ANALGESICS® ASSET

OXFORD, 1st August 2022 — Eptiva Therapeutics Ltd., the first company to apply a precision medicine approach to developing new pain therapeutics, announces today that they have signed a licensing agreement with To Better Days Ltd. for worldwide exclusive rights to develop and commercialize their proprietary transdermal cholecalciferol patch in prescription indications.

Eptiva Therapeutics have utilized their proprietary Personalized Analgesics® platform to identify a novel application for topical calcitriol in a range of specific pain disorders. Eptiva's new research highlights the key role of calcitriol in pain signaling pathways through modulation of neuron, immune cell and keratin cell signaling to produce local analgesic actions independent of systemic deficiency status.

Under the terms of the agreement Eptiva Therapeutics Ltd. have been granted a fully paid up royalty free worldwide license from To Better Days Ltd. for their proprietary transdermal cholecalciferol patch in prescription indications. The patented patch has a unique dosage form, which produces a novel profile to safely provide long lasting local calcitriol exposure for therapeutic use.

The new program is a first-in-class non-opioid analgesic devoid of abuse potential and CNS side effects and comes with a pre-clinical and Phase I clinical data package. Eptiva have identified a range of specific pain disorders with strong target to disease links for further development; including rare / orphan pain indications, as well as stratified patient groups of large chronic pain indications with an estimated annual peak sales potential from \$100 million to \$1 billion.

About Eptiva Therapeutics

Eptiva Therapeutics Ltd. is the first to apply a precision medicine approach to developing new pain therapeutics. The company was established in Oxford UK in 2020 by Mark J. Field (former SVP Pain R&D at Grünenthal, and a.o. key contributor to Lyrica & Neurontin) and Harald F. Stock (a.o. former CEO of Grünenthal, biotech co-founder and board member). Eptiva's de-risked portfolio includes both, in-house assets and in-licensing options, based on its proprietary Personalized Analgesics® technology platform. Each program targets multi-modal mechanisms, with local delivery, in high-value peripheral pain patient groups – creating potent analgesics, devoid of CNS side effects. Our research platform has recently been externally validated in a research collaboration with Bayer Pharmaceuticals.

For more information go to www.eptivatx.com or contact harald@eptivatx.com